| Daniel Anthony Blaz, FNP-BC | |
|
431 Meadowlark St, Shaw Afb, SC 29152-5019 | |
| (803) 885-7976 | |
| Not Available |
| Full Name | Daniel Anthony Blaz |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 18 Years |
| Location | 431 Meadowlark St, Shaw Afb, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881786879 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | RN279151 (Ohio) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 09219 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Medina Hospital | Medina, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
| Cleveland Clinic - Wooster | 6800708124 | 247 |
News Archive
Nutrastar International Inc., a leading producer and supplier of premium branded Traditional Chinese Medicine consumer products, today announced record financial results for the quarter ended March 31, 2011.
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.
A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.
› Verified 9 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
Nutrastar International Inc., a leading producer and supplier of premium branded Traditional Chinese Medicine consumer products, today announced record financial results for the quarter ended March 31, 2011.
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.
A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.
› Verified 9 days ago
| Entity Name | Wooster Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033135009 PECOS PAC ID: 6800708124 Enrollment ID: O20031211000578 |
News Archive
Nutrastar International Inc., a leading producer and supplier of premium branded Traditional Chinese Medicine consumer products, today announced record financial results for the quarter ended March 31, 2011.
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.
A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Anthony Blaz, FNP-BC 431 Meadowlark St, Shaw Afb, SC 29152-5019 Ph: (330) 858-3514 | Daniel Anthony Blaz, FNP-BC 431 Meadowlark St, Shaw Afb, SC 29152-5019 Ph: (803) 885-7976 |
News Archive
Nutrastar International Inc., a leading producer and supplier of premium branded Traditional Chinese Medicine consumer products, today announced record financial results for the quarter ended March 31, 2011.
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.
A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.
› Verified 9 days ago
Ms. Lauren Carol Allain, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 431 Meadowlark St., 20th Mdg/sghc, Shaw Afb, SC 29152 Phone: 803-895-6356 Fax: 803-895-6456 | |
Jacqueline Mintz, ARNP-FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 524 Nelson Ave, Shaw Afb, SC 29152 Phone: 706-495-6612 | |
Kimberly Marie Shanks, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 431 Meadowlark Rd, Shaw Afb, SC 29152 Phone: 803-895-6592 | |
Bri Durrans Deamare Ramirez, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 420 Polifka Dr, Shaw Afb, SC 29152 Phone: 808-772-9388 |